Practice-changing at #ESMO26 Presidential @ProfGLongMIA
INTerpath-001: personalized mRNA neoantigen Tx (intismeran) + pembro vs pembro alone in resected stage IIB–IV melanoma (n=1,137)
RFS HR 0.58, 2-yr RFS 82% vs 70%
DMFS HR 0.62, 2-yr DMFS 89% vs 80%
It's the 1st phase 3 win for an individualized cancer vaccine against an active IO control.
OS is pending, but the adjuvant melanoma bar just moved. Kudos to the entire team!
Moving moment as @ProfGLongMIA paid tribute to Dr. Jeff Weber, who designed this trial and enrolled patients until his passing. Jeff was a dear friend and my colleague at @MoffittNews and today's results are his legacy 💙
Bladder next: INTerpath-005 in MIUC, look forward to seeing the data in future!
232 views · 1 like · 1 repost · 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: Shilpa Gupta · x.com